Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan Pharmaceuticals has introduced Gilead Sciences' Sovaldi (sofosbuvir 400mg tablets) in India for the treatment of chronic hepatitis C infection, a blood-borne infectious disease.
Subscribe to our email newsletter
Sovaldi is indicated to treat chronic hepatitis C infection as a component of a combination antiviral treatment regimen.
In February 2015, Gilead appointed Mylan as its exclusive distributor of Sovaldi in India, where it is estimated that around 12 million people are chronically infected with hepatitis C.
Mylan president Rajiv Malik said: "Mylan has a long-standing history of partnering with Gilead to tackle key public health issues in India and around the world, beginning with expanding access to high quality, affordable HIV/AIDS antiretrovirals and now extending our partnership to include hepatitis C treatments.
"We are proud to continue our work together with the launch of Sovaldi as it supports our joint commitment to meeting the unmet medical needs of patients in India."
The company said that Sovaldi is sold by its dedicated sales force as part of its Hepato Care segment.